# Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

> **NCT05245903** · — · RECRUITING · sponsor: **Mclean Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Alzheimer Disease
- Dementia Alzheimers
- Dementia
- Cognitive Impairment
- Mild Cognitive Impairment
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Neurocognitive Dysfunction
- Cognitive Dysfunction
- Mental Disorder

## Interventions

- **DEVICE:** Emerald Device Monitoring

## Key facts

- **NCT ID:** NCT05245903
- **Lead sponsor:** Mclean Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-31
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245903, "Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05245903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*